2.50
price up icon11.11%   0.25
after-market 시간 외 거래: 2.60 0.10 +4.00%
loading
전일 마감가:
$2.25
열려 있는:
$2.25
하루 거래량:
901.78K
Relative Volume:
3.96
시가총액:
$69.61M
수익:
$875.70K
순이익/손실:
$-39.57M
주가수익비율:
-0.3877
EPS:
-6.4491
순현금흐름:
$-33.65M
1주 성능:
+2.88%
1개월 성능:
-4.21%
6개월 성능:
-22.36%
1년 성능:
-50.30%
1일 변동 폭
Value
$2.23
$2.55
1주일 범위
Value
$2.22
$2.55
52주 변동 폭
Value
$2.22
$5.86

Vistagen Therapeutics Inc Stock (VTGN) Company Profile

Name
명칭
Vistagen Therapeutics Inc
Name
전화
650-577-3600
Name
주소
343 ALLERTON AVENUE, SOUTH SAN FRANCISCO
Name
직원
45
Name
트위터
@vistagen
Name
다음 수익 날짜
2024-11-07
Name
최신 SEC 제출 서류
Name
VTGN's Discussions on Twitter

VTGN을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
VTGN
Vistagen Therapeutics Inc
2.50 69.61M 875.70K -39.57M -33.65M -1.3423
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
397.27 102.31B 10.63B -479.80M -1.35B -1.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
701.85 77.13B 13.85B 4.65B 3.32B 40.41
Biotechnology icon
ARGX
Argen X Se Adr
623.82 37.30B 1.86B -40.29M -1.28B -0.85
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
245.44 31.66B 2.09B -332.26M 16.06M -2.62
Biotechnology icon
BNTX
Biontech Se Adr
113.08 27.11B 3.30B -501.07M 1.03B -2.1146

Vistagen Therapeutics Inc Stock (VTGN) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2023-12-07 업그레이드 Jefferies Hold → Buy
2023-08-07 업그레이드 Maxim Group Hold → Buy
2022-07-22 다운그레이드 Jefferies Buy → Hold
2022-07-22 다운그레이드 Robert W. Baird Outperform → Neutral
2022-07-22 다운그레이드 William Blair Outperform → Mkt Perform
2021-05-20 개시 Robert W. Baird Outperform
2021-02-18 개시 Jefferies Buy
2021-01-04 업그레이드 William Blair Mkt Perform → Outperform
2018-06-27 개시 Maxim Group Buy
2018-02-08 재확인 Chardan Capital Markets Buy
2017-03-28 개시 Maxim Group Buy
모두보기

Vistagen Therapeutics Inc 주식(VTGN)의 최신 뉴스

pulisher
Dec 19, 2024

VTGN stock touches 52-week low at $2.38 amid market challenges - Investing.com India

Dec 19, 2024
pulisher
Dec 12, 2024

Mental Disorder Treatment Market Innovations and Key Players: - openPR

Dec 12, 2024
pulisher
Dec 12, 2024

PD-LID Market Growth to Accelerate in Forecast Period - openPR

Dec 12, 2024
pulisher
Dec 11, 2024

VTGN Stock Touches 52-Week Low at $2.47 Amid Market Challenges By Investing.com - Investing.com South Africa

Dec 11, 2024
pulisher
Dec 10, 2024

VTGN Stock Touches 52-Week Low at $2.47 Amid Market Challenges - Investing.com

Dec 10, 2024
pulisher
Nov 30, 2024

VTGN (Vistagen Therapeutics) Inventory Turnover : 0.00 (As of Sep. 2024) - GuruFocus.com

Nov 30, 2024
pulisher
Nov 27, 2024

Vistagen Therapeutics, Inc. (NASDAQ:VTGN) Shares Sold by Great Point Partners LLC - MarketBeat

Nov 27, 2024
pulisher
Nov 26, 2024

Analyzing Vistagen Therapeutics (NASDAQ:VTGN) and Daré Bioscience (NASDAQ:DARE) - Defense World

Nov 26, 2024
pulisher
Nov 22, 2024

VTGN Stock Touches 52-Week Low at $2.51 Amid Market Challenges - Investing.com India

Nov 22, 2024
pulisher
Nov 21, 2024

Anxiety drug trials keep Stifel optimistic on VistaGen stock's upside potential - Investing.com Canada

Nov 21, 2024
pulisher
Nov 21, 2024

Reviewing Vistagen Therapeutics (NASDAQ:VTGN) and Minerva Neurosciences (NASDAQ:NERV) - Defense World

Nov 21, 2024
pulisher
Nov 17, 2024

Vistagen Therapeutics, Inc. (NASDAQ:VTGN) Short Interest Down 18.1% in October - Defense World

Nov 17, 2024
pulisher
Nov 15, 2024

Great Point Partners LLC Increases Stake in Vistagen Therapeutics Inc - GuruFocus.com

Nov 15, 2024
pulisher
Nov 15, 2024

Citadel Advisors LLC Increases Stake in Vistagen Therapeutics Inc - GuruFocus.com

Nov 15, 2024
pulisher
Nov 14, 2024

Vistagen Therapeutics adds SKDK, GCI Health alum Michelle Peters Wellington - MM+M Online

Nov 14, 2024
pulisher
Nov 14, 2024

Vistagen CEO to Present at Stifel 2024 Healthcare Conference | VTGN Stock News - StockTitan

Nov 14, 2024
pulisher
Nov 14, 2024

Vistagen to Present at the Stifel 2024 Healthcare Conference - Business Wire

Nov 14, 2024
pulisher
Nov 11, 2024

VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Q2 2025 Earnings Call Transcript - Insider Monkey

Nov 11, 2024
pulisher
Nov 11, 2024

Q1 Earnings Estimate for VTGN Issued By William Blair - MarketBeat

Nov 11, 2024
pulisher
Nov 08, 2024

VistaGen Therapeutics, Inc. (VTGN) Reports Q2 Loss, Misses Revenue Estimates - MSN

Nov 08, 2024
pulisher
Nov 08, 2024

Vistagen Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2024 - Marketscreener.com

Nov 08, 2024
pulisher
Nov 08, 2024

Vistagen Therapeutics Inc (VTGN) Q2 2025 Earnings Call Highlight - GuruFocus.com

Nov 08, 2024
pulisher
Nov 08, 2024

Vistagen Therapeutics Inc (VTGN) Q2 2025 Earnings Call Highlights: Navigating Challenges with a ... - Yahoo Finance

Nov 08, 2024
pulisher
Nov 08, 2024

Vistagen Therapeutics Inc (VTGN) Q2 2025 Earnings Call Highlights: Navigating Challenges with a ... By GuruFocus - Investing.com Canada

Nov 08, 2024
pulisher
Nov 08, 2024

Vistagen Therapeutics Reports Increased R&D Expenses - TipRanks

Nov 08, 2024
pulisher
Nov 07, 2024

Vistagen Therapeutics Inc Reports Q2 2025 Revenue of $183,000, M - GuruFocus.com

Nov 07, 2024
pulisher
Nov 07, 2024

Vistagen Reports Fiscal Year 2025 Second Quarter Financial Results and Corporate Update - Business Wire

Nov 07, 2024
pulisher
Nov 07, 2024

Vistagen reports Q2 EPS (42c), consensus (39c) - TipRanks

Nov 07, 2024
pulisher
Nov 06, 2024

Vistagen Therapeutics Inc (VTGN) Q2 2025 Earnings Report Preview: What to Expect - GuruFocus.com

Nov 06, 2024
pulisher
Nov 05, 2024

Vistagen to Present at the 2024 Neuroscience Education Institute Congress - Business Wire

Nov 05, 2024
pulisher
Nov 05, 2024

Vistagen to Present Breakthrough SAD Treatment Data at 2024 NEI Congress - StockTitan

Nov 05, 2024
pulisher
Nov 02, 2024

Vistagen Therapeutics (VTGN) Scheduled to Post Earnings on Thursday - MarketBeat

Nov 02, 2024
pulisher
Nov 01, 2024

Vistagen to Report Fiscal Year 2025 Second Quarter Results and Host Corporate Update Conference Call on November 7, 2024 - sharewise

Nov 01, 2024
pulisher
Oct 31, 2024

VTGN (Vistagen Therapeutics) Profitability Rank : 1 (As of Jun. 2024) - GuruFocus.com

Oct 31, 2024
pulisher
Oct 21, 2024

Generalized Anxiety Disorder Pipeline 2024: Clinical Trials - openPR

Oct 21, 2024
pulisher
Oct 15, 2024

Vistagen Could Run Up Ahead Of Phase 3 Results In Social Anxiety Disorder - Seeking Alpha

Oct 15, 2024
pulisher
Oct 12, 2024

VistaGen Therapeutics (VTGN) Upgraded to Buy: Here's What You Should Know - MSN

Oct 12, 2024
pulisher
Oct 11, 2024

Mental Disorder Treatment Market Global Industry Forecast - openPR

Oct 11, 2024
pulisher
Oct 10, 2024

Vistagen, The Goldie Hawn Foundation, and MindUP students Rings the Nasdaq Stock Market Closing Bell on World Mental Health Day - Nasdaq

Oct 10, 2024
pulisher
Oct 09, 2024

Vistagen Therapeutics Inc (VTGN) Q1 2025 Earnings Call Highlights: Navigating Growth and Challenges - Yahoo Finance UK

Oct 09, 2024
pulisher
Oct 09, 2024

Vistagen, The Goldie Hawn Foundation, and MindUP Students to Ring Nasdaq Closing Bell on World Mental Health Day - sharewise

Oct 09, 2024
pulisher
Sep 24, 2024

Great Point Partners LLC Has $5.32 Million Stock Holdings in Vistagen Therapeutics, Inc. (NASDAQ:VTGN) - Defense World

Sep 24, 2024
pulisher
Sep 24, 2024

Vistagen enrols first subject in Phase III trial of social anxiety disorder drug - Yahoo Finance

Sep 24, 2024
pulisher
Sep 24, 2024

Vistagen advances phase 3 trial for social anxiety treatment By Investing.com - Investing.com Australia

Sep 24, 2024
pulisher
Sep 23, 2024

Vistagen advances phase 3 trial for social anxiety treatment - Investing.com

Sep 23, 2024

Vistagen Therapeutics Inc (VTGN) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
$17.87
price down icon 2.88%
$68.84
price up icon 2.65%
$39.39
price down icon 0.43%
$359.58
price down icon 0.16%
$176.50
price up icon 1.02%
$113.08
price up icon 1.56%
자본화:     |  볼륨(24시간):